CDK4/6 inhibitors and hormone therapy in hormone receptor-positive advanced breast cancer: Real-world data and intrinsic subtypes defined by PAM50.

Tamara Díaz Redondo,Rocío Lavado-Valenzuela,Maria Emilia Dominguez Recio,Sofia Ruiz,Encarnación González Flores,José Antonio López-López,Vanessa de Luque,Cristina Morales-Estevez,Marta Robles-Lasarte,Jesús Perales-Adán,Enrique Saez Lara,Martina Álvarez,Alfonso Sánchez-Muñoz,Ana Godoy,Ester Villar,Francisco Carabantes,José Manuel Baena-Cañada,José M. Jerez,Nuria Ribelles,Emilio Alba

CDK4/6 inhibitors and hormone therapy in hormone receptor-positive advanced breast cancer: Real-world data and intrinsic subtypes defined by PAM50.

2020

e13035Background: CDK 4/6 inhibitors plus hormone therapy(HT) has been approved by FDA and EMA for the treatment of hormone receptor positive HER2 negative advanced breast cancer (HR+/HER2-BC) with...

Keywords:

Cancer
Oncology
real world data
advanced breast
Hormone therapy
Pathology
Internal medicine
Medicine
Hormone receptor
Cyclin-dependent kinase
HER2 negative

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations